C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
1. A pharmaceutical composition comprising about 400 U/mL to about 600 U/mL of C1 esterase inhibitor, a citrate buffer or a phosphate buffer, and a pH range from about 6.5 to about 8.0, wherein said composition is for subcutaneous administration, and wherein the composition is for hereditary angioedema (HAE) prophylactic treatment in a subject in need thereof.
2. The composition of claim 1 , wherein the buffer is the citrate buffer.
3. The composition of claim 1 , wherein the buffer is the phosphate buffer.
4. The composition of claim 1 , wherein the buffer comprises sodium citrate.
5. The composition of claim 1 , wherein citrate is present at about 5 mM to about 50 mM.
6. The composition of claim 5 , wherein citrate is present at about 10 mM to about 30 mM.
7. The composition of claim 5 , wherein citrate is present at about 7 mM to about 13 mM.
8. The composition of claim 7 , wherein citrate is present at about 10 mM.
9. The composition of claim 1 , wherein the composition further comprises at least one amino acid or salt thereof.
10. The composition of claim 1 , wherein the C1 esterase inhibitor comprises an amino acid sequence more than 90% identical to residues 23 to 500 of SEQ ID NO: 1.
11. The composition of claim 10 , wherein the C1 esterase inhibitor comprises an amino acid sequence at least 95% identical to residues 23 to 500 of SEQ ID NO: 1.
12. The composition of claim 11 , wherein the C1 esterase inhibitor comprises the amino acid sequence of residues 23 to 500 of SEQ ID NO: 1.
13. The composition of claim 1 , wherein the C1 esterase inhibitor is present at about 600 U/mL.
14. The composition of claim 1 , wherein the C1 esterase inhibitor is present at about 500 U/mL.
15. The composition of claim 1 , wherein the C1 esterase inhibitor is present at about 400 U/mL.
16. The composition of claim 1 , wherein the C1 esterase inhibitor is present at about 400 U/mL to about 500 U/mL.
17. The composition of claim 1 , wherein the C1 esterase inhibitor is present at about 500 to about 600 U/mL.
18. The composition of claim 1 , wherein the composition comprises about 1,000 U to about 3,500 U of the C1 esterase inhibitor.
19. The composition of claim 1 , wherein the composition comprises about 1,500 U to about 2,500 U of the C1 esterase inhibitor.
20. The composition of claim 1 , wherein the composition comprises about 100 U to about 5,000 U of the C1 esterase inhibitor.
21. The composition of claim 1 , wherein the composition comprises about 250 U to about 2,000 U of the C1 esterase inhibitor.
22. The composition of claim 1 , wherein the composition comprises about 250 U to about 1,000 U of the C1 esterase inhibitor.
23. The composition of claim 1 , wherein the composition comprises about 2000 to about 3000 U of the C1 esterase inhibitor.
24. The composition of claim 1 , wherein the composition comprises about 2000 U of the C1 esterase inhibitor.
25. The composition of claim 1 , wherein the composition comprises about 5000 U of the C1 esterase inhibitor.
26. The composition of claim 1 , for increasing the level of C1 esterase inhibitor in the blood of a subject in need thereof.
27. The composition of claim 1 , wherein the pH ranges from about 6.5 to about 7.5.
28. The composition of claim 1 , wherein the pH ranges from about 6.5 to about 7.
29. A lyophilized pharmaceutical composition comprising sodium citrate, and at least 2000 U of C1 esterase inhibitor and less than 5000 U of C1 esterase inhibitor, wherein following reconstitution, said lyophilized composition achieves a solution comprising: (i) a concentration of about 400 to about 600 U/mL of C1 esterase inhibitor, (ii) citrate at a concentration of about 5 mM to about 15 mM, and (iii) a pH ranging from about 6.5 to about 8.0, wherein the solution is for subcutaneous administration to treat HAE and wherein the C1 esterase inhibitor comprises the amino acid sequence of residues 23 to 500 of SEQ ID NO: 1.
30. The lyophilized pharmaceutical composition of claim 29 , wherein the pH of the solution ranges from about 6.5 to about 7.5.
31. The lyophilized pharmaceutical composition of claim 29 , wherein the pH of the solution ranges from about 6.5 to about 7.
32. The lyophilized pharmaceutical composition of claim 29 , wherein the concentration of citrate in the solution is about 7 mM to about 13 mM.
33. The lyophilized pharmaceutical composition of claim 32 , wherein the concentration of citrate in the solution is about 10 mM.
34. The lyophilized pharmaceutical composition of claim 29 , wherein the composition is for HAE prophylactic treatment.
35. The lyophilized pharmaceutical composition of claim 29 , wherein the pH of the solution is about 6.9.